Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-12-26
pubmed:abstractText
The in vitro activity of moxifloxacin against 923 recent anaerobic isolates obtained from pretreatment cultures in patients with complicated intra-abdominal infections was studied using the CLSI M11-A-6 agar dilution method. Moxifloxacin was active against 87% (96 of 110) Bacteroides fragilis strains at < or = 1 microg/ml and 87% (79 of 90) B. thetaiotaomicron strains at < or = 2 microg/ml. Species variation was seen, with B. uniformis, B. vulgatus, Clostridium clostridioforme, and C. symbiosum being least susceptible and accounting for most of the resistant isolates; excluding the aforementioned four resistant species, 86% (303 of 363) of Bacteroides species isolates and 94% (417 of 450) of all other genera and species were susceptible to < or = 2 microg/ml of moxifloxacin. Overall, moxifloxacin was active against 763 of 923 (83%) of strains at < or = 2 microg/ml, supporting its use as a monotherapy for some community-acquired intra-abdominal infections.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-10795599, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-10817736, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-11353648, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-11418523, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-12234859, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-12499183, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-12865399, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-14523762, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-14729746, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-14982797, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-15056642, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-15150181, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-15206059, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-2406869, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-8957575, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-8980763, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-9056020, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-9210683, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-9372419, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-9421311, http://linkedlifedata.com/resource/pubmed/commentcorrection/16377680-9665302
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
148-55
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
pubmed:affiliation
R. M. Alden Research Laboratory, 2021 Santa Monica Blvd., Suite #740 East, Santa Monica, California 90404, USA. ejcgmd@aol.com
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't